Checks fatty liver risk in people with type 2 diabetes in routine care
Follows adults with type 2 diabetes treated with dapagliflozin and pioglitazone.
Key facts
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Where
- Andong and Seoul, South KoreaSee the 2 sites
- Trial code
- Registry title
- A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 30 Sept 2024
- Expected to end
- Mar 2027
- Type of study
- Observational
- Record updated
- 18 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who are scheduled to start a fixed-dose combination of dapagliflozin/pioglitazone. It studies the risk of fatty liver disease (NAFLD) and how useful this combination is.
- Age
- 19 years and older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes.
- Earlier treatment
- People must not have taken the fixed-dose combination of dapagliflozin/pioglitazone before the start of the study (visit 1).
Main reasons for not taking part
- Has a history of taking the fixed-dose combination of dapagliflozin/pioglitazone at visit 1
- Is expected to need insulin during the study
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
- Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study
Who cannot take part
- Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
- Those who are expected to need insulin prescription during the study period
Where in South Korea
- Andong HospitalAndong, South KoreaContact: Joong-kyung SungTaking people
- Konkuk University Medical CenterSeoul, South KoreaContact: Kee-ho SongNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
- Plain-language title
- Checks fatty liver risk in people with type 2 diabetes in routine careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 October 2024